3.005
Annexon Inc stock is traded at $3.005, with a volume of 1.14M.
It is down -3.06% in the last 24 hours and up +24.17% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$3.10
Open:
$3.12
24h Volume:
1.14M
Relative Volume:
0.70
Market Cap:
$330.21M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.6977
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
-5.50%
1M Performance:
+24.17%
6M Performance:
+101.68%
1Y Performance:
-59.28%
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ANNX
Annexon Inc
|
3.005 | 340.65M | 0 | -134.24M | -121.34M | -1.77 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
Oct-30-23 | Initiated | Wells Fargo | Overweight |
May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-16-22 | Initiated | Jefferies | Buy |
Sep-09-22 | Initiated | BTIG Research | Buy |
Nov-30-21 | Initiated | H.C. Wainwright | Buy |
Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Jan-26-21 | Initiated | Needham | Buy |
Aug-18-20 | Initiated | BofA Securities | Buy |
Aug-18-20 | Initiated | Cowen | Outperform |
Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Is Annexon Inc. stock a defensive play in 2025Inflation Watch & Free Expert Verified Stock Movement Alerts - newser.com
Is it time to cut losses on Annexon Inc.Trade Analysis Report & Expert Approved Momentum Ideas - newser.com
Is Annexon Inc. stock poised for growthEarnings Growth Summary & Weekly Market Pulse Updates - newser.com
How geopolitical tensions affect Annexon Inc. stockPortfolio Gains Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Will Annexon Inc. stock deliver better than expected guidanceJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - newser.com
Key metrics from Annexon Inc.’s quarterly dataPortfolio Risk Report & Reliable Entry Point Alerts - newser.com
Analyzing drawdowns of Annexon Inc. with statistical toolsJuly 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Should you wait for a breakout in Annexon Inc.Stock Surge & Risk Adjusted Buy/Sell Alerts - newser.com
What data driven models say about Annexon Inc.’s futureWatch List & Verified Momentum Stock Alerts - newser.com
Full technical analysis of Annexon Inc. stockJuly 2025 Sentiment & Free Reliable Trade Execution Plans - newser.com
Annexon Inc.’s volatility index tracking explainedDollar Strength & Safe Capital Growth Trade Ideas - newser.com
Will Annexon Inc. outperform the marketIPO Watch & Weekly Market Pulse Alerts - newser.com
Why Annexon Inc. stock is seen as undervaluedJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
Annexon's (ANNX) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Does Annexon Inc. show high probability of reboundOil Prices & Short-Term High Return Ideas - newser.com
Will Annexon Inc. stock outperform Nasdaq indexEarnings Risk Summary & Technical Buy Zone Confirmation - newser.com
Will Annexon Inc. stock maintain momentum in 2025Rate Cut & Reliable Breakout Forecasts - newser.com
Is Annexon Inc. stock entering bullish territory2025 Trade Ideas & Fast Exit and Entry Trade Guides - newser.com
Is Annexon Inc. stock bottoming out2025 Dividend Review & Weekly Market Pulse Updates - newser.com
Statistical indicators supporting Annexon Inc.’s strengthPortfolio Value Summary & Consistent Profit Trading Strategies - newser.com
J. Safra Sarasin Holding AG Purchases 126,903 Shares of Annexon, Inc. $ANNX - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Price action breakdown for Annexon Inc.2025 Price Momentum & Reliable Volume Spike Trade Alerts - newser.com
Annexon, Inc. $ANNX Holdings Lifted by Park Avenue Securities LLC - Defense World
Annexon (NASDAQ:ANNX) Director Acquires $12,550.75 in Stock - MarketBeat
Insider Buying: William Carson Acquires Shares of Annexon Inc (A - GuruFocus
Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition - Insider Monkey
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annexon Inc Stock (ANNX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Carson William H. | Director |
Sep 02 '25 |
Buy |
2.09 |
4,115 |
8,600 |
37,945 |
Carson William H. | Director |
Jul 30 '25 |
Buy |
2.43 |
4,115 |
9,999 |
33,830 |
Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Jul 14 '25 |
Sale |
2.58 |
1,116 |
2,879 |
105,084 |
Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Jul 14 '25 |
Sale |
2.58 |
1,117 |
2,882 |
121,616 |
Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Jul 14 '25 |
Sale |
2.61 |
853 |
2,226 |
130,689 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):